<abstract xmlns="http://www.w3.org/1999/xhtml"><p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) is prone to thrombotic events with pathogenic mechanism that are still incompletely understood. Occurrence of antiphospholipid antibodies, especially anticardiolipin antibodies, was described in many viral infections and could be part of the chain in micro-thrombosis occurrence in COVID-19. We herein present three cases of COVID-19 patients without any known immune background. For two of the patients, the laboratory tests show neither inflammatory syndrome, nor elevated D-dimer. Even if pauci-symptomatic patients, pulmonary involvement in as much as 10 - 25% was identified on chest computer tomography exam. In addition, a third patient, with more important pulmonary involvement (25-50%), inflammatory response and elevated D-dimer levels is presented. None of the patients had prolonged activated partial-thromboplastin time. IgM and/ or IgG anticardiolipin antibodies were found positives in all three cases.</p></abstract>

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) is prone to thrombotic events with pathogenic mechanism that are still incompletely understood. Occurrence of antiphospholipid antibodies, especially anticardiolipin antibodies, was described in many viral infections and could be part of the chain in micro-thrombosis occurrence in COVID-19. We herein present three cases of COVID-19 patients without any known immune background. For two of the patients, the laboratory tests show neither inflammatory syndrome, nor elevated D-dimer. Even if pauci-symptomatic patients, pulmonary involvement in as much as 10 - 25% was identified on chest computer tomography exam. In addition, a third patient, with more important pulmonary involvement (25-50%), inflammatory response and elevated D-dimer levels is presented. None of the patients had prolonged activated partial-thromboplastin time. IgM and/ or IgG anticardiolipin antibodies were found positives in all three cases.

Anticardiolipin Antibodies in COVID-19 – Report of Three Cases

“Carol Davila” University of Medicine and Pharmacy

Internal Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"Anticardiolipin Antibodies in COVID-19 \u2013 Report of Three Cases"}

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) is prone to thrombotic events with pathogenic mechanism that are still...

Anticardiolipin Antibodies in COVID-19 – Report of Three Cases

Pubblicato online: 13 mar 2021

Pagine: 59 - 67

DOI: https://doi.org/10.2478/inmed-2021-0151

Parole chiave
SARS-CoV-2, antiphospholipid syndrome, lupus coagulant inhibitor, thrombosis, pneumonia

© 2021 Alina Dima et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Anticardiolipin Antibodies in COVID-19 – Report of Three Cases

Pubblicato online: 13 mar 2021

Pagine: 59 - 67

DOI: https://doi.org/10.2478/inmed-2021-0151

Parole chiaveSARS-CoV-2, antiphospholipid syndrome, lupus coagulant inhibitor, thrombosis, pneumonia

© 2021 Alina Dima et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Parole chiave
SARS-CoV-2, antiphospholipid syndrome, lupus coagulant inhibitor, thrombosis, pneumonia